To simplify the comparison of RAS/ERK signaling properties between cancer cells, Bugaj et al. [23] used an elegant strategy of activating RAS optogenetically at the level of RAS and simultaneously monitoring ERK activation via the nuclear translocation of FP-tagged ERK. Here, MAPK1 is linked to cancer.